DeepMed Research

British Columbia Cancer Agency

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

DOTATOC PET/CT for Imaging NET Patients

Recruiting

Conditions: Neuroblastoma
Ganglioneuroma
Medulloblastoma
Insulinoma
Paraganglioma
Merkel Cell Carcinoma
Neuroendocrine Tumors
Vipoma
Pheochromocytoma
Medullary Carcinoma

Interventions: Diagnostic Test: 68Ga-DOTATOC PET/CT
Diagnostic Test: 18F-FDG PET/CT

First Posted Date: 2018-07-11

Last Posted Date: 2024-11-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 800

Registration Number: NCT03583528

Locations: 🇨🇦
BC Cancer, Vancouver, British Columbia, Canada

Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Phase 2

Conditions: Invasive Breast Cancer
Arthralgia
Chemotherapeutic Toxicity
Myalgia

Interventions: Drug: Gabapentin 300mg

First Posted Date: 2018-06-25

Last Posted Date: 2018-06-25

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 46

Registration Number: NCT03566394

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

Phase 1

Terminated

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: SLC-0111
Drug: Gemcitabine Injection

First Posted Date: 2018-03-01

Last Posted Date: 2024-05-24

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 6

Registration Number: NCT03450018

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦
BC Cancer - Vancouver, Vancouver, British Columbia, Canada

LDR vs. HDR Brachytherapy for Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: High dose rate prostate brachytherapy
Radiation: Low dose rate prostate brachytherapy

First Posted Date: 2018-02-08

Last Posted Date: 2025-03-13

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 140

Registration Number: NCT03426748

Locations: 🇨🇦
British Columbia Cancer Agency Center for the Southern Interior, Kelowna, British Columbia, Canada

OCT-AF Imaging of Pre-cancers of Vulva and Cervix

Terminated

Conditions: Cervical Dysplasia
Precancerous Lesions
Vulvar Cancer
Vulvar Dysplasia
Cervical Cancer

Interventions: Device: OCT-AFI

First Posted Date: 2017-09-18

Last Posted Date: 2024-03-18

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 20

Registration Number: NCT03285841

Locations: 🇨🇦
Vancouver General Hospital Women's Clinic, Vancouver, British Columbia, Canada

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Phase 1

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Radiation: Focal radiotherapy
Drug: Durvalumab

First Posted Date: 2017-09-15

Last Posted Date: 2018-07-11

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 22

Registration Number: NCT03283943

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Partial Prostate Salvage High Dose Rate Brachytherapy

Not Applicable

Recruiting

Conditions: Recurrent Prostate Cancer

Interventions: Radiation: HDR partial prostate brachytherapy

First Posted Date: 2017-08-11

Last Posted Date: 2025-03-13

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 30

Registration Number: NCT03246802

Locations: 🇨🇦
BCCA Center for the Southern Interior, Kelowna, British Columbia, Canada

Innovative Approach to Triage Oral Precancer

Conditions: Oral Cancer
Oral Premalignant Lesion

First Posted Date: 2017-06-29

Last Posted Date: 2017-06-29

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 360

Registration Number: NCT03202810

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

Phase 2

Conditions: Resectable Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Metformin Hydrochloride 500Mg Tablet

First Posted Date: 2016-12-01

Last Posted Date: 2018-01-18

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 20

Registration Number: NCT02978547

Locations: 🇨🇦
BC Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

Not Applicable

Active, not recruiting

Conditions: Metastatic Tumors

Interventions: Radiation: Stereotactic Ablative Body Radiotherapy

First Posted Date: 2016-10-14

Last Posted Date: 2024-07-29

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 399

Registration Number: NCT02933242

Locations: 🇨🇦
BC Cancer, Prince George, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy